These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 17227490

  • 1. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J.
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [Abstract] [Full Text] [Related]

  • 2. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R, Nayyar R, Kumar V, Gupta NP, Hemal AK, Jagannathan NR, Dattagupta S, Thulkar S.
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [Abstract] [Full Text] [Related]

  • 3. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G.
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
    Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB.
    J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
    [Abstract] [Full Text] [Related]

  • 5. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW, Andriole GL, Ratliff TL, Catalona WJ.
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [Abstract] [Full Text] [Related]

  • 6. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy.
    Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, Carroll PR.
    Urology; 1996 Oct; 48(4):594-9. PubMed ID: 8886066
    [Abstract] [Full Text] [Related]

  • 7. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
    Cirillo S, Petracchini M, Della Monica P, Gallo T, Tartaglia V, Vestita E, Ferrando U, Regge D.
    Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
    [Abstract] [Full Text] [Related]

  • 8. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT.
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
    Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, Holmberg L, Scandinavian Prostate Cancer Group Study No. 4.
    J Natl Cancer Inst; 2007 Apr 04; 99(7):526-32. PubMed ID: 17405997
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb 04; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Feb 04; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 12. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 04; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
    Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.
    Prostate; 2005 Aug 01; 64(3):240-5. PubMed ID: 15712213
    [Abstract] [Full Text] [Related]

  • 14. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.
    Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT.
    BJU Int; 2007 Apr 01; 99(4):786-93. PubMed ID: 17223922
    [Abstract] [Full Text] [Related]

  • 15. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging.
    Costouros NG, Coakley FV, Westphalen AC, Qayyum A, Yeh BM, Joe BN, Kurhanewicz J.
    AJR Am J Roentgenol; 2007 Mar 01; 188(3):812-6. PubMed ID: 17312072
    [Abstract] [Full Text] [Related]

  • 16. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Nishimoto K, Nakashima J, Hashiguchi A, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Oya M, Murai M.
    Int J Urol; 2008 Jun 01; 15(6):520-3. PubMed ID: 18422574
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
    Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR.
    J Urol; 1997 May 01; 157(5):1740-3. PubMed ID: 9112517
    [Abstract] [Full Text] [Related]

  • 19. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.
    Contemp Clin Trials; 2009 Jan 01; 30(1):81-7. PubMed ID: 18783735
    [Abstract] [Full Text] [Related]

  • 20. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy.
    Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, Carroll PR, Hricak H, Kurhanewicz J.
    Radiology; 2004 Jan 01; 230(1):215-20. PubMed ID: 14695396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.